(TheNewswire)
Calgary, Alberta – TheNewswire - May 18, 2022 - Ocumetics Technology Corp. (“ Ocumetics ”)( TSXV:OTC) is pleased to provide an update onthe status of preclinical studies for its first product, the BionicLens.
Since January 2022, Ocumetics has been busy undertakinga series of studies using cadaver donor eyes to determine howOcumetics’ optical technologies would fit in the human eye. Thesestudies have led to design enhancements to perfect how the Bionic Lensconforms to the lens capsular bag of the human eye.
The studies, and resulting design enhancements, weresupervised by Ocumetics’ regulatory approval expert, Dr. BarbaraFant, Ocumetics’ founder and Chief Scientific Officer, Dr. GarthWebb, and Chief Medical Officer, Dr. Doyle Stulting.
“We are focused on perfecting the design of the lenstechnology before we begin the regulatory approval process, which weexpect will begin shortly,” said Dr. Barbara Fant.
Dr. Garth Webb added, “We have been experimentingwith different lens materials, and combinations thereof, to ensure wehave optimized the quality of the optics and the accommodation levelswe are seeking in the lens technology. We have also been experimentingwith different types of lens injectors to ensure the ophthalmologistcan maintain control of the injection process during surgery.”
The ergonomics of installing the optical technologieshas also been an emphasis over the past 4-6 weeks.
“We have received excellent feedback from theophthalmologists performing the cadaver surgeries,” says Dr. DoyleStulting. “We have used this feedback to ensure the process ofinserting the Bionic Lens into the eye is as easy and intuitive aspossible. If ophthalmologists enjoy the surgical process of installingthe Bionic Lens into the patient’s eye, they are much more likely torecommend Ocumetics products to their patients.”
“It has been a busy few months since our lastupdate,” said Ocumetics CEO, Dr. Mark Lee. “We could not behappier with the progress being made. Moreover, we remain on targetfor the first human studies, the Proof of Concept, to begin later thisfall. All-in-all, very encouraging news for both our investors and thefuture users of Ocumetics’ optical technologies.”
About Ocumetics
Ocumetics Technology Corp. ( TSXV:“OTC”) is a Canadian researchand product development company that specializes in adaptive lensdesigns. Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry - the BionicLens. The Bionic Lens is an expandable intraocular lens that fitswithin the natural lens compartment of the eye potentially toeliminate the need for corrective lenses. It is designed to allowthe eye’s natural muscle activity to shift focus from distance tonear.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theclinical trial program outlined above and that it will be conducted asexpected. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.